Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... The severe flooding that devastated a wide swath of ... the bridges, roads and other infrastructure had been upgraded ... University of Colorado Denver. , "People need to understand ... PhD, associate professor of structural engineering at the CU ... author the study. "There is an assumption that a ...
(Date:10/27/2014)... Kalorama Information says that PCR is demonstrating ... the United States and is the ... said the FDA,s Emergency Use Authorization (EUA) to authorize the ... detection of the Ebola virus was an indication that ... the IVD industry and its biennial survey on diagnostics ...
(Date:10/27/2014)... 2014 Pressure BioSciences, Inc. (OTCQB: PBIO) ... the development and sale of high pressure-based sample ... today announced that Professor Ruedi Aebersold ... reproducible, and robust method to allow – for ... on small needle biopsy samples by mass spectrometry ...
(Date:10/25/2014)... The report “Adipic Acid Market by ... Global Trends & Forecast to 2019” report analyzes ... drivers, opportunities, and trends in different regions. , ... spread through 217 slides and in-depth TOC on ... to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early buyers will ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... that going from a positive to a negative is a ... scientists from the National Institute of Standards and Technology (NIST) ... extended the reach of their novel microfluidic system for analyzing ... how the system, meant to analyze real-world, crude mixtures such ...
... help resolve the public debate over America,s future light source ... compact fluorescent lamp. It could be neither. ... new breed of light emitting diode, or LED, that conjures ... an article in the current online issue of the journal ...
... Ariz., Aug. 31, 2011 SynCardia Systems, Inc. ( www.syncardia.com ... today that it has launched company pages on Facebook ... to educate a larger audience about the world,s only FDA, ... have been more than 950 implants of the Total Artificial ...
Cached Biology Technology:Researchers expand capabilities of miniature analyzer for complex samples 2Manufacturing method paves way for commercially viable quantum dot-based LEDs 2Manufacturing method paves way for commercially viable quantum dot-based LEDs 3SynCardia Goes Social on Facebook, Twitter and LinkedIn 2SynCardia Goes Social on Facebook, Twitter and LinkedIn 3SynCardia Goes Social on Facebook, Twitter and LinkedIn 4
(Date:10/28/2014)... of Health (NIH) announced awards to expand the ... National Center for Advancing Translational Sciences (ORDR-NCATS) collaborative ... the network, physician scientists at 22 consortia will ... clinical research and investigate new treatments for patients ... by $29 million in fiscal 2014 funding from ...
(Date:10/27/2014)... researchers have delivered a scientific one-two punch with a ... self-assemble via their sticky ends. , Collagen is the ... bone and the fibrous tissues that support cells and ... better synthetic collagen for tissue engineering and cosmetic and ... has been studying synthetic collagen for a decade, teasing ...
(Date:10/27/2014)... 27, 2014) — Recent breakthroughs may pave the ... infected by parasitic helminths. These flatworms, including tapeworms ... and blood flukes (schistosomes), infect more than 300 ... life years lost due to chronic illness and ... , professor of microbiology, immunology, and tropical medicine, ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3GW researcher adapting breakthrough technologies to combat parasitic worm infections 2
... of the brain are over-stimulated and this leads to ... this process was finally shown last year to be ... stroke. But very few targets for drugs to block ... detailed study, researchers have discovered a previously missing link ...
... an evolutionary geneticist at Fred Hutchinson Cancer Research Center who ... with opposing functions that drives evolutionary change has been ... is among 27 of the nation,s top biomedical scientists to ... more than 1,100 applicants. , "HHMI has a very ...
... Solanaceaea flowering plant family with some species producing foods ... effect against Parkinson,s disease. The study appearing today in ... American Neurological Association and Child Neurology Society, suggests that ... nicotine, such as peppers and tomatoes, may reduce risk ...
Cached Biology News:Researchers discover a missing link in signals contributing to neurodegeneration 2Fred Hutch evolutionary geneticist Harmit Malik selected as an HHMI investigator 2Fred Hutch evolutionary geneticist Harmit Malik selected as an HHMI investigator 3Could eating peppers prevent Parkinson's? 2
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
D4-GDI rabbit polyclonal antibody...
Biology Products: